Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Charles River Labs ( (CRL) ) is now available.
On February 18, 2026, Charles River Laboratories announced the appointment of Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026. Coleman brings more than 30 years of financial and operational management experience, including senior leadership roles at Premier, Inc., Dentsply Sirona Inc., Integra LifeSciences, Curtiss-Wright, and Alcatel-Lucent, and he is a Certified Public Accountant.
Under an at-will offer letter, Coleman will receive an annual base salary of $800,000, eligibility for a target bonus equal to 85% of his 2026 base salary, and a 2026 equity award valued at $3 million, split between Performance Share Units and Restricted Stock Units. He will also receive a $1.875 million one-time cash award paid in two installments and a $3.5 million new-hire RSU grant vesting over four years, as he succeeds interim CFO Michael G. Knell, who returns full-time to his role as Corporate Senior Vice President and Chief Accounting Officer.
The most recent analyst rating on (CRL) stock is a Buy with a $251.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.
Spark’s Take on CRL Stock
According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.
The score is held back primarily by deteriorating financial performance (declining revenue and negative profitability) and an unfavorable/less interpretable valuation signal (negative P/E). These are partially offset by constructive technical trend strength and a mixed-to-positive earnings call focused on cost savings, portfolio actions, and buybacks that could improve margins and EPS even amid muted top-line guidance.
To see Spark’s full report on CRL stock, click here.
More about Charles River Labs
Charles River Laboratories operates in the healthcare and life sciences sector, providing research, development, and related services to support pharmaceutical, biotech, and medical technology companies. The company focuses on enabling drug discovery and development, with a global customer base that relies on its scientific, operational, and regulatory expertise.
Average Trading Volume: 800,181
Technical Sentiment Signal: Sell
Current Market Cap: $7.94B
See more insights into CRL stock on TipRanks’ Stock Analysis page.